Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834 Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202006495409011 Date of Approval: 25/06/2020
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title A study to test three experimental HIV vaccines in healthy adults
Official scientific title A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa.
Brief summary describing the background and objectives of the trial The Phase 1 clinical trial HIV-CORE (COnserved REgions) 006 is a trial of a new combined vaccine HIVconsvX to determine safety and immunogenicity in healthy adults in Kenya, Uganda and Zambia. Immune responses may vary between populations and so it is important to confirm that the vaccines are suitable for the people and environment where they will be deployed for protection against HIV/AIDS. There are many different strains of HIV-1, and the virus can change to escape immune responses. This vaccine regimen is designed to work in all parts of the world. Objectives: PRIMARY Safety • To evaluate the safety and tolerability of a prime boost vaccine regimen utilizing non-replicating simian adenovirus (ChAdOx1) followed by non-replicating poxvirus modified vaccinia virus Ankara (MVA) in adults in Eastern and Southern Africa Immunogenicity • To evaluate the specific T-cell immune responses induced by the ChAdOx1.tHIVconsv1 followed by MVA.tHIVconsv3&4 vaccines in vaccine recipients. SECONDARY • To assess tHIVconsvX-specific T-cell responses of for their frequency, breadth and duration in vaccine recipients. • To assess functional T-cell responses in vaccine recipients that inhibit replication in vitro of viruses of major HIV-1 clades A, B, C and D. EXPLORATORY • To assess induction of plurifunctional tHIVconsvX-specific memory T cells in the vaccine recipients. • Characterization of the gut microbiome composition and richness. • Feasibility of recruiting required sample size across all sites within 16 weeks • Feasibility of retaining at least 90% of enrolled volunteers to end of study.
Type of trial RCT
Acronym (If the trial has an acronym then please provide) Phase 1
Disease(s) or condition(s) being studied Infections and Infestations
Sub-Disease(s) or condition(s) being studied HIV/AIDS
Purpose of the trial Prevention: Vaccines
Anticipated trial start date 29/06/2020
Actual trial start date 15/07/2021
Anticipated date of last follow up 31/12/2021
Actual Last follow-up date 02/11/2022
Anticipated target sample size (number of participants) 88
Actual target sample size (number of participants) 89
Recruitment status Completed
Publication URL Not Applicable
Secondary Ids Issuing authority/Trial register
P 863 10 2019 Kenyatta National Hospital University of Nairobi Ethics Committee
CT089 19DMS 7 9 22CT Zambia Medicines Regulatory Authority ZAMRA
495 2019 University of Zambia Biomedical Research Ethics Committee
GC 127 20 02 761 Uganda Virus Research Institute UVRI
OXTREC 56 19 Oxford Tropical Research Ethics Committee
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Parallel: different groups receive different interventions at same time during study Randomised Simple randomization using a randomization table created by a computer software program Allocation was determined by the holder of the sequence who is situated off site Masking/blinding used Outcome Assessors,Participants
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group ChAdOx1.tHIVconsv1 vaccine and Two vaccine components MVA.tHIVconsv3 and MVA.tHIVconsv4 ChAdOx1.tHIVconsv1, 5.0 x1010 vp, (Week 0) MVA.tHIVconsv3, 1.0 x 108 pfu, (Week 4) MVA.tHIVconsv4,0.9 x 108 pfu, (Week 4) Volunteers will receive two injections with half dose into the deltoid region of each arm of ChAdOx1.tHIVconsv1 or placebo at enrolment (week 0), and two injections (MVA.tHIVconsv3 or placebo into one deltoid region and MVA.tHIVconsv4 or placebo into the other) at 4 weeks. The ChAdOx1.tHIVconsv1 vaccine utilizes non-replicating engineered simian adenovirus vaccine vector ChAdOx1 derived from simian adenovirus (SAdV) serotype Y25 of chimpanzee origin to deliver a mosaic immunogen tHIVconsv1 derived from functionally conserved regions of HIV-1 proteins. Two vaccine components MVA.tHIVconsv3 and MVA.tHIVconsv4 complement each other and will be used as a pair for immunizations. They utilize non-replicating poxvirus MVA delivering bi-valent mosaic immunogens, either tHIVconsv3 or tHIVconsv4, derived from functionally conserved regions of HIV-1 proteins. 72
Control Group Sodium Chloride Volunteers will receive two injections with half dose into the deltoid region of each arm of placebo at enrolment (Week 0) and two injections of placebo into one deltoid region and into the other at 4 weeks. Volunteers will be randomised to receive placebo at 2 vaccination visits 4 weeks apart. (Week 0 and 4). Normal Saline (Sodium Chloride) 16 Active-Treatment of Control Group
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
• Healthy male and female as assessed by a medical history, physical exam, and laboratory tests. • At low risk of HIV infection and willing to maintain low-risk behaviour for the duration of the trial. Individuals from key populations are not excluded provided they are assessed to be at low risk of HIV infection at screening and are willing to maintain low-risk behaviour during the study. • At least 18 years of age on the day of screening and have not reached their 51st birthday on the day of the first vaccination. • Willing and able to give informed consent for participation in the trial before any study-related procedures are performed. Volunteers will pass an Assessment of Understanding before signing the consent form. • Willing to comply with the requirements of the protocol and be available for follow up for the planned duration of the study. • Willing to undergo HIV testing, risk reduction counselling, receive HIV test results • All sexually active males (unless anatomically sterile or in a monogamous relationship with a female partner who uses a documented non-barrier method of birth control) must be willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until 4 months after the last vaccination. • If a female of childbearing potential, willing to use an effective non-barrier method of contraception (hormonal contraceptive or intrauterine device) from at least 2 weeks prior to first vaccination until at least 4 months after the last study vaccination. If not of childbearing potential: postmenopausal (>45 years of age with amenorrhea for at least 2 years, or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone [FSH] level >40 IU/L) or surgically sterile: no additional contraception required. • All female volunteers must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Procedures and must test negative prior to each s Confirmed HIV-1 or HIV-2 infection • Receipt of any vaccine in the previous 28 days or planned receipt within 28 days of Investigational Medicinal Product. • Participation in another clinical trial of an Investigational Medicinal Product currently, within the previous 3 months or expected participation during the study. • Receipt of another investigational HIV vaccine candidate or investigational adenoviral vectored vaccine (Note: receipt of an HIV vaccine placebo will not exclude a volunteer from participation if documentation is available and the Medical Monitor gives approval). • Receipt of blood transfusion or blood-derived products within the previous 4 months or expectation of receiving blood products during the study period. • Receipt of immunoglobulin products within the previous 3 months. • If female, pregnant or planning a pregnancy during the period of enrolment until 4 months after the last study vaccination; or lactating. • Any clinically relevant abnormality on history or examination such as: • Any confirmed or suspected history of immunodeficiency including recurrent severe infections; • Use of systemic corticosteroids for >14 days (use of topical or inhaled steroids is permitted) within the previous 6 months; • Immunosuppressive, anti-cancer, anti-tuberculosis or other medications considered significant by the investigator within the previous 6 months. • History of splenectomy. • History of autoimmune disease • History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, or clinically significant arrhythmia (including any arrhythmia requiring medication, treatment, or clinical follow up). • History of cancer (except basal cell carcinoma of the skin) • Asthma that is not well controlled. • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine • History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis, respiratory difficulty, angioedema). Adolescent: 13 Year-18 Year,Adult: 19 Year-44 Year,Middle Aged: 45 Year(s)-64 Year(s) 18 Year(s) 50 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 20/04/2020 Kenyatta National Hospital University of Nairobi Ethics Research Committee
Ethics Committee Address
Street address City Postal code Country
P.O.BOX 20723 Nairobi 00202 Kenya
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome 1. Proportion of volunteers who experience local and systemic reactogenicity events 2. Proportion of vaccine recipients developing HIV-1 specific T-cell responses 3. Proportion of volunteers with vaccine related serious adverse events (SAEs) 4. Proportion of vaccine recipients developing HIV-1 specific T-cell responses 1.Within 7 days post vaccination. 2. Through 28 days post final vaccination. 3.Throughout the study period,. 4. At week 1 and 40 weeks post final vaccination.
Secondary Outcome 1. Frequency, breadth and duration of T-cell responses to conserved epitopes measured in the IFN-γ ELISPOT assay in each vaccine recipient 2. Breadth of inhibition of HIV-1 viruses representative of circulating viruses in Kenya, Uganda and Zambia and other global clades in the in vitro Virus Inhibition Assay 1. At 1 and 40 weeks post final vaccination. 2. At 1 and 40 weeks post final vaccination.
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Zambia Emory HIV Research Project B22/F737 Mwembelelo Road Lusaka, Zambia Lusaka 10101 Zambia
Kenya AIDS Vaccine Institute for Clinical Research College of Health Sciences, University of Nairobi PO Box 19676- 00202, Nairobi, Kenya Nairobi 00202 Kenya
Kenya Medical Research Institute Wellcome Trust PO Box 230, Kilifi, Kenya Kilifi 80108 Kenya
Medical Research and Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit. Plot 5159 Nakiwogo Road, Entebbe, Uganda Entebbe 00000 Uganda
FUNDING SOURCES
Name of source Street address City Postal code Country
European Developing Countries Clinical Trials Partnership Anna van Saksenlaan, 51 , post code 2593 HW.Hague Netherlands Hague 2593 Netherlands
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor University of Oxford Wellington Square, Oxford, OX1 2JD Oxford 441865 United Kingdom University
COLLABORATORS
Name Street address City Postal code Country
University of Nairobi PO Box 19676- 00202, Nairobi, Kenya Nairobi 00202 Kenya
KEMRI Wellcome Trust Research Programme PO Box 230, Kilifi, Kenya Kilifi 8010 Kenya
Zambia Emory HIV Research Project B22/F737 Mwembelelo Road Lusaka 00000 Zambia
MRC UVRI and LSHTM Uganda Research Unit Plot 5159 Nakiwogo Road, Entebbe, Uganda Entebbe 00000 Uganda
Centre for Immunology Vaccinology Imperial College Lift Bank D Chelsea Westminster NHS Foundation Trust 369 Fulham Road London SW10 9NH London 4420 United Kingdom
IAVI 125 Broad Street, 9th Floor New York, NY 10004 USA New York 1212 United States of America
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator Paola Cicconi paola.cicconi@ndm.ox.ac.uk 441865611413 Churchill Hospital, Old Road Oxford OX3 7LE
City Postal code Country Position/Affiliation
Oxford 441865 United Kingdom Chief Investigator
Role Name Email Phone Street address
Scientific Enquiries Tom Hanke tomas.hanke@ndm.ox.ac.uk 441865617630 Roosevelt Drive Oxford OX3 7DQ
City Postal code Country Position/Affiliation
Oxford 441865 United Kingdom Chief Non Clinical Investigator
Role Name Email Phone Street address
Public Enquiries Hester Kuipers hkuipers@iavi.org 31205210030 Van Diemenstraat 48 1013 NH, Amsterdam
City Postal code Country Position/Affiliation
Amsterdam 1013 Netherlands Executive Director
Role Name Email Phone Street address
Principal Investigator Walter Jaoko wjaoko@kaviuon.org +254727555254 PO Box 19676-00202 Off Ngong Road, Nairobi Kenya
City Postal code Country Position/Affiliation
Nairobi 00202 Kenya Principal Investigator
Role Name Email Phone Street address
Principal Investigator William Kilembe wkilembe@rzhrg-mail.org +260966851820 Zambia Emory HIV Research Project B22/F737 Mwembelelo Road Emmasdale, Lusaka Zambia
City Postal code Country Position/Affiliation
Lusaka 0211 Zambia Principal Investigator
Role Name Email Phone Street address
Principal Investigator Pontiano Kaleebu Pontiano.Kaleebu@mrcuganda.org +256417704103 P.O.BOX 49 Entebbe, Uganda
City Postal code Country Position/Affiliation
Entebbe 0000 Uganda Principal Investigator
Role Name Email Phone Street address
Principal Investigator Eduard Sanders ESanders@kemri-wellcome.org +254723593762 P.O. Box 230-80108 Kilifi, Kenya.
City Postal code Country Position/Affiliation
kilifi 80108 Kenya Principal Investigator
Role Name Email Phone Street address
Scientific Enquiries Vincent Muturi Kioi VMuturi-Kioi@iavi.org +254719043000 IAVI Africa, The Address, 11th Floor, Waiyaki way
City Postal code Country Position/Affiliation
Nairobi 00202 Kenya Medical Monitor Senior Medical Director
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes Study information will be made available through an open repository. The information to be made available will be anonymized so that there is no link to participants and will include data on safety, immune responses and any other data generated from samples obtained in this study. Study Protocol Within 12 months of the study completion date we will provide the additional document types as described above. Aim is to provide a summary of the results or a link to summary results within the trial registration record.
URL Results Available Results Summary Result Posting Date First Journal Publication Date
No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information